News & Announcements MorphImmune, Inc., a Research Bridge Partners Portfolio Company, Appoints Ronald Martell as President and CEO Research Bridge Partners’ Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio Advances Dr. Lola Eniola-Adefeso’s Immune Cell Targeted Therapeutic Platform Research Bridge Partners Makes Seed Capital Investment In Erisyon, Inc. Research Bridge Partners Makes Seed Investment in Eradivir, Inc. Research Bridge Partners Makes Seed Capital Investment In Novosteo, Inc. Research Bridge Partners Launches Seed Fund To Catalyze Commercialization Of Mid-Continent Research
